Sanofi (NASDAQ:SNY) Stock Holdings Raised by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc raised its stake in Sanofi (NASDAQ:SNYFree Report) by 15.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,067 shares of the company’s stock after purchasing an additional 948 shares during the period. Pinnacle Financial Partners Inc’s holdings in Sanofi were worth $351,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Clearbridge Investments LLC boosted its stake in Sanofi by 8.4% during the 3rd quarter. Clearbridge Investments LLC now owns 184,630 shares of the company’s stock valued at $9,904,000 after purchasing an additional 14,362 shares during the period. Dynamic Advisor Solutions LLC bought a new stake in shares of Sanofi during the 4th quarter worth about $2,104,000. Soros Fund Management LLC bought a new stake in shares of Sanofi during the 3rd quarter worth about $11,533,000. Clear Street Markets LLC raised its position in shares of Sanofi by 352.8% during the 3rd quarter. Clear Street Markets LLC now owns 130,183 shares of the company’s stock worth $6,983,000 after buying an additional 101,430 shares in the last quarter. Finally, BKM Wealth Management LLC bought a new stake in shares of Sanofi in the 4th quarter worth approximately $237,000. 10.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SNY. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Morgan Stanley initiated coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $55.00.

Check Out Our Latest Stock Analysis on SNY

Sanofi Trading Up 0.5 %

Shares of SNY stock opened at $47.96 on Thursday. The firm has a fifty day moving average of $47.94 and a 200-day moving average of $49.20. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 52-week low of $42.63 and a 52-week high of $57.82. The stock has a market cap of $121.32 billion, a price-to-earnings ratio of 20.32, a P/E/G ratio of 1.77 and a beta of 0.61.

Sanofi (NASDAQ:SNYGet Free Report) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. On average, equities research analysts forecast that Sanofi will post 4.19 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is 58.47%.

About Sanofi

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Articles

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.